Leading Independent Investment Research, Morningstar, Inc.

Morningstar

Leading Independent Investment Research

Morningstar, Inc.

Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. We offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors. 

Morningstar provides data on more than 500,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 16 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries, with more than $180 billion in assets under advisement or management as of June 30, 2015. We have operations in 27 countries.

Download the Morningstar Fact Sheet : http://corporate.morningstar.com/US/documents/MarketingFactSheets/AboutMorningstarFactsheet.pdf

Equity Bottom-Up

<p>We’ve slightly lowered our <a href="https://www.smartkarma.com/entities/11747" target="_blank" data-smartkarma-citation="entities:11747:1">Takeda Pharmaceutical Co Ltd (4502 JP)</a> fair value estimate to JPY 5,100 from JPY 5,400 after incorporating the close of the <a href="https://www.smartkarma.com/entities/22142" target="_blank" data-smartkarma-citation="entities:22142:1">Shire PLC (SHP LN)</a> acquisition before the end of Takeda’s fiscal 2018 (we assume early calendar 2019) and mixed expectations for Takeda’s own portfolio this year and beyond, following the release of its fiscal 2017 financial results. Regarding Takeda’s valuation impact from the Shire acquisition, we think the deal is fairly neutral to our…</p>

We’ve slightly lowered our Takeda Pharmaceutical Co Ltd (4502 JP) fair value estimate to JPY 5,100 from JPY 5,400 after incorporating the close of the Shire PLC (SHP LN) acquisition before the end of Takeda’s fiscal 2018 (we assume early calendar 2019) and mixed expectations for Takeda’s own portfolio this year and beyond, following the release of its fiscal 2017 financial results. Regarding Takeda’s valuation impact from the Shire acquisition, we think the deal is fairly neutral to our…

Takeda FVE Reduction Leaves Shares Slightly Undervalued; Shire Acquisition Neutral to Valuation